Avantor, Inc. (NYSE: AVTR), one of the largest providers of laboratory supplies, chemicals, and services to the global life sciences and advanced technology industries, reported first-quarter 2026 results on April 29 that beat Wall Street expectations and sent its stock surging more than 6% in premarket trading — a welcome signal for a company that has spent much of the past year navigating difficult market conditions and executing a broad operational transformation.
Net sales for the quarter ended March 31, 2026 came in at $1.581 billion, flat compared to the prior-year period but ahead of analyst consensus of approximately $1.54 billion. Adjusted earnings per share of $0.17 topped the $0.16 estimate. Adjusted EBITDA reached $219.4 million, surpassing expectations of roughly $207.9 million. Full financial details are available in the Q1 2026 Earnings Presentation and Supplemental Non-GAAP Disclosures on Avantor's investor relations site.
"First quarter results exceeded our expectations due to improved execution in Bioscience and Medtech Products, and we saw stabilization in VWR," said Emmanuel Ligner, President and Chief Executive Officer. "Revival is already having a positive impact, and I am encouraged by the momentum and positive energy across the organization."
Related Coverage: What Danaher's Q1 2026 Earnings Mean for Lab Managers: Bioprocessing Turns a Corner Danaher's Q1 2026 results signal a bioprocessing equipment rebound, with order growth exceeding 30% year-over-year — contextualizing the broader demand environment that shapes Avantor's own recovery timeline. |
What "revival" means for lab buyers
For laboratory managers and procurement professionals who depend on Avantor's VWR brand for day-to-day consumables, reagents, and equipment, the Revival transformation program is particularly relevant. Launched in 2025, Revival is a company-wide operational overhaul built around five pillars: investing in manufacturing and supply chain infrastructure, strengthening leadership accountability, simplifying operations, optimizing the portfolio, and evolving go-to-market strategy.
In Q1 alone, the company conducted eight weeks of Kaizen continuous improvement events, established a formal Capex Council to prioritize investments with the strongest returns, and sanctioned 12 capital projects. A North American manufacturing facility automation initiative is targeting a greater than 35% increase in process capacity and a more than 50% reduction in operator requirements. For labs that track supply chain resilience as a key procurement risk factor, these operational changes could have downstream implications for availability and lead times on VWR-branded consumables over the next 12–18 months.
Approximately 25% of Avantor's top 60 leaders have been refreshed since Revival launched, including new appointments across the Chief Operating Officer, Chief Procurement Officer, Chief Digital Officer, and key commercial roles within its BMP and VWR businesses. The company notes these changes are self-funded through productivity gains, with company-wide headcount down 2% year-to-date.
Lab Safety Management Certificate
The Lab Safety Management certificate is more than training—it’s a professional advantage.
Gain critical skills and IACET-approved CEUs that make a measurable difference.
Segment breakdown: BMP leads, VWR stabilizes
Segment | Revenue Q1'26 | YoY Reported | Organic Growth | Adj. OI Margin |
VWR Distribution & Services | $1,150.0M | –0.4% | –4.8% | 9.2% |
Bioscience & Medtech Products (BMP) | $431.4M | +1.2% | –2.0% | 23.8% |
Avantor operates through two main reporting segments. The VWR Distribution & Services segment generated $1.150 billion in Q1 revenue — a slight reported decrease of 0.4% year-over-year. On an organic basis (adjusting for favorable currency impacts), the decline was 4.8%. Adjusted operating income in the segment was $105.4 million, a 9.2% margin, down from $147.9 million a year ago. Labs that rely on VWR as a primary distribution channel and want to understand how to optimize procurement under current conditions can find relevant guidance on Lab Manager.
The Bioscience & Medtech Products segment — which covers Avantor's proprietary materials, bioprocessing products, and medtech components — showed better momentum. Revenue rose 1.2% on a reported basis to $431.4 million. Adjusted operating income of $102.7 million translated to a 23.8% adjusted operating margin. For labs involved in bioprocessing and biomanufacturing, BMP is the segment most likely to affect product availability and pricing across upstream and downstream consumable categories.
Interested in life sciences?
Full-year outlook reaffirmed despite volume headwinds
Despite a quarter in which organic sales declined across both business units — the result of persistent softness in lab supply demand following the post-COVID normalization cycle — Avantor maintained its fiscal 2026 financial guidance in full. The company is targeting organic revenue growth in the range of negative 2.5% to negative 0.5%, with reported growth expected to be slightly positive on the back of approximately 1% currency tailwinds. Budget-conscious lab managers who are also contending with tariff-driven cost increases in 2026 may find Avantor's guidance language around pricing and FX worth monitoring closely in coming quarters.
Adjusted EBITDA margin is targeted in the 14.8% to 15.3% range for the full year — meaningfully above the 13.9% reported in Q1, implying significant operational leverage and Revival productivity savings expected to flow through in subsequent quarters. Adjusted EPS guidance of $0.77 to $0.83 and free cash flow of $500 million to $550 million (excluding restructuring costs) round out the full-year framework. The full 8-K SEC filing and investor relations calendar are available for those following the investment angle.
Supply chain and service expansion: What's already in motion
Revival isn't Avantor's only active initiative with direct implications for labs. Earlier this year, the company opened a new Centralized Service Center in Watertown, Massachusetts — a facility offering outsourced lab support services including media preparation, glassware washing, autoclaving, and chemical management for research institutions across the Greater Boston area. The expansion reflects a broader push by Avantor to build recurring, service-based revenue alongside its distribution business, while providing labs with scalable solutions for non-core operational tasks.
Avantor has also invested in AI-assisted inventory management and smart shelf technology, which the company describes as tools that allow labs to automate consumable tracking and reorder cycles. Lab managers exploring these options can review Avantor's own perspective on unlocking lab efficiency through integrated services.
What lab managers should watch
For procurement and operations professionals in research, academic, and biopharma laboratory settings, several threads from this earnings report are worth tracking:
• Supply chain stability: Revival's investment in manufacturing automation and procurement leadership could improve availability and lead times on VWR-branded consumables over the next 12–18 months. See our guide to building a resilient lab supply chain.
• Pricing and contract terms: Labs on multi-year VWR contracts should monitor for product rationalization changes as Avantor continues to simplify its portfolio. Our procurement best practices guide covers how to build contract flexibility into lab supply agreements.
• BMP product pipeline: The Bioscience and Medtech Products segment is positioned as Avantor's growth engine. Labs in bioprocessing, cell therapy, and medtech development should monitor new product launches from this segment closely.
• Tariff exposure: While Avantor has not cited tariffs as a material headwind in Q1 2026, the broader industry impact is real. Lab Manager's in-depth coverage of how rising tariffs are reshaping laboratory budgets for 2026 is directly relevant.
• Lab expansion planning: Labs that depend on Avantor/VWR as a primary supplier and are planning expansions should factor supply lead times into their procurement timelines. Our guide to equipping a lab expansion addresses how to forecast consumable burn rates and negotiate contracts ahead of growth.
• Leadership transitions: The ongoing CFO transition and continued leadership refresh may affect account management relationships; labs should confirm key contacts with their Avantor/VWR representatives.
• Organic demand recovery: Q2 2026 results, expected in late July, will be the next meaningful data point. Context from the Danaher Q1 2026 earnings analysis — where bioprocessing equipment orders grew more than 30% year-over-year — suggests the sector cycle may be turning, which would benefit Avantor's VWR and BMP segments alike.
About Avantor Avantor, Inc. (NYSE: AVTR) is a global provider of mission-critical products and services to the life sciences and advanced technology industries, operating in more than 180 countries with over 300,000 customer locations worldwide. Its principal distribution brand, VWR, is one of the most widely used laboratory supply channels in the world. Avantor is headquartered in Radnor, Pennsylvania. Visit Avantor's corporate site → Source links: Q1 2026 Press Release | Earnings Presentation (PDF) | Supplemental Disclosures (PDF) | Investor Relations |
